Clinical Trial Update: A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC [Phase 2]

View source ↗

Summary

A Phase II randomized trial is evaluating neoadjuvant Ivonescimab or Penpulimab plus chemotherapy in resectable non-small cell lung cancer, with the study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)
• Penpulimab

Snippet

Sponsor: Yang Fan, MD | Conditions: NSCLC, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING